IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer

  • Baharlou, Rasoul (Department of Immunology and Microbiology, School of Medicine, Jahrom University of Medical Sciences) ;
  • Vasmehjani, Abbas Ahmadi (Department of Immunology and Microbiology, School of Medicine, Jahrom University of Medical Sciences) ;
  • Dehghani, Ali (Department of Nursing, School of Nursing, Jahrom University of Medical Sciences) ;
  • Ghobadifar, Mohamed Amin (Department of Student Research Committee, School of Medicine, Jahrom University of Medical Sciences) ;
  • Khoubyari, Mahshid (Department of Student Research Committee, School of Medicine, Jahrom University of Medical Sciences)
  • Received : 2014.05.06
  • Accepted : 2014.06.04
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-${\beta}$) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-${\beta}$ were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p<0.0001) and TGF-${\beta}$ (p<0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.

Keywords

References

  1. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 2005. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 175: 5-14.
  2. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141. https://doi.org/10.1038/ni1261
  3. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Fili, S. Ferri, F. Frosali, F. Giudici, P. Romagnani, P. Parronchi, F. Tonelli, E. Maggi, and S. Romagnani. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861. https://doi.org/10.1084/jem.20070663
  4. Peck, A. and E. D. Mellins. 2009. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin. Immunol. 132: 295-304. https://doi.org/10.1016/j.clim.2009.03.522
  5. Sfanos, K. S., T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn, A. M. DeMarzo, A. K. Meeker, W. B. Isaacs, and C. G. Drake. 2008. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14: 3254-3261. https://doi.org/10.1158/1078-0432.CCR-07-5164
  6. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178: 6730-6733. https://doi.org/10.4049/jimmunol.178.11.6730
  7. Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8: 337-348. https://doi.org/10.1038/nri2295
  8. Nam, J. S., M. Terabe, M. J. Kang, H. Chae, N. Voong, Y. A. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68: 3915-3923. https://doi.org/10.1158/0008-5472.CAN-08-0206
  9. Shime, H., M. Yabu, T. Akazawa, K. Kodama, M. Matsumoto, T. Seya, and N. Inoue. 2008. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 180: 7175-7183. https://doi.org/10.4049/jimmunol.180.11.7175
  10. Passos, S. T., J. S. Silver, A. C. O'Hara, D. Sehy, J. S. Stumhofer, and C. A. Hunter. 2010. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 184: 1776-1783. https://doi.org/10.4049/jimmunol.0901843
  11. Mucida, D. and H. Cheroutre. 2007. TGFbeta and retinoic acid intersect in immune-regulation. Cell Adh. Migr. 1: 142-144. https://doi.org/10.4161/cam.1.3.5062
  12. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057. https://doi.org/10.1038/nature07036
  13. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, D. Blanchard, C. Gaillard, B. Das Mahapatra, E. Rouvier, P. Golstein, J. Banchereau, and S. Lebecque. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183: 2593-2603. https://doi.org/10.1084/jem.183.6.2593
  14. Murugaiyan, G. and B. Saha. 2009. Protumor vs antitumor functions of IL-17. J. Immunol. 183: 4169-4175. https://doi.org/10.4049/jimmunol.0901017
  15. Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, G. and Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537. https://doi.org/10.1016/j.bbrc.2008.07.060
  16. Honorati, M. C., S. Neri, L. Cattini, and A. Facchini. 2006. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts1. Osteoarthritis Cartilage 14: 345-352. https://doi.org/10.1016/j.joca.2005.10.004
  17. Jeon, S. H., B. C. Chae, H. A. Kim, G. Y. Seo, D. W. Seo, G. T. Chun, N. S. Kim, S. W. Yie, W. H. Byeon, S. H. Eom, K. S. Ha, Y. M. Kim, and P. H. Kim. 2007. Mechanisms underlying TGF-${\beta}1$-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J. Leukoc. Biol. 81: 557-566. https://doi.org/10.1189/jlb.0806517
  18. Wang, L., T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206: 1457-1464. https://doi.org/10.1084/jem.20090207
  19. Radosavljevic, G., B. Ljujic, I. Jovanovic, Z. Srzentic, S. Pavlovic, N. Zdravkovic, M. Milovanovic, D. Bankovic, M. Knezevic, L. J. Acimovic, and N. Arsenijevic. 2010. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57: 135-144. https://doi.org/10.4149/neo_2010_02_135
  20. Jovanovic, D. V., J. A. Di Battista, J. Martel-Pelletier, F. C. Jolicoeur, Y. He, M. Zhang, F. Mineau, and J. P. Pelletier. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160: 3513-3521.
  21. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. W. Kerstann, L. Feigenbaum, C. C. Chan, and N. P. Restifo. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373. https://doi.org/10.1182/blood-2007-11-120998
  22. Ankathatti Munegowda M, Deng Y, Mulligan SJ, and Xiang J. 2011. Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol. Immunother. 60: 1473-1484. https://doi.org/10.1007/s00262-011-1054-y
  23. Kolahdoozan S, Sadjadi A, Radmard AR, and Khademi H. 2010. Five common cancers in Iran. Arch. Iran. Med. 13: 143-146.
  24. Zhang, J. P., J. Yan, J. Xu, X. H. Pang, M. S. Chen, L. Li, C. Wu, S. P. Li, and L. Zheng. 2009. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50: 980-989. https://doi.org/10.1016/j.jhep.2008.12.033
  25. Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, and G. Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537. https://doi.org/10.1016/j.bbrc.2008.07.060
  26. Zhu, X., L. A. Mulcahy, R. A. Mohammed, A. H. Lee, H. A. Franks, L. Kilpatrick, A. Yilmazer, E. C. Paish, I. O. Ellis, P. M. Patel, and A. M. Jackson. 2008. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10: R95. https://doi.org/10.1186/bcr2195
  27. Kato, T., H. Furumoto, T. Ogura, Y. Onishi, M. Irahara, S. Yamano, M. Kamada, and T. Aono. 2001. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282: 735-738. https://doi.org/10.1006/bbrc.2001.4618
  28. Chi, L. J., H. T. Lu, G. L. Li, X. M. Wang, Y. Su, W. H. Xu, and B. Z. Shen. 2010. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin. Exp. Immunol. 161: 480-489. https://doi.org/10.1111/j.1365-2249.2010.04215.x
  29. Lee, J. J., Y. L. Chang, W. L. Lai, J. Y. Ko, M. Y. Kuo, C. P. Chiang, M. Azuma, C. W. Chen, and J. S. Chia. 2011. Increased prevalence of interleukin-17-producing $CD4^+$ tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 33: 1301-1308. https://doi.org/10.1002/hed.21607
  30. Kwon, K. A., S. H. Kim, S. Y. Oh, S. Lee, J. Y. Han, K. H. Kim, R. Y. Goh, H. J. Choi, K. J. Park, M. S. Roh, H. J. Kim, H. C. Kwon, and J. H. Lee. 2010. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10: 203. https://doi.org/10.1186/1471-2407-10-203
  31. Ravishankaran, P. and R. Karunanithi. 2011. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol. 9: 18. https://doi.org/10.1186/1477-7819-9-18
  32. Chen, M. F., P. Y. Lin, C. F. Wu, W. C. Chen, and C. T. Wu. 2013. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 8: e61901. https://doi.org/10.1371/journal.pone.0061901
  33. Yang, L., Y. Qi, J. Hu, L. Tang, S. Zhao, and B. Shan. 2012. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem. Biophys. 62: 153-159. https://doi.org/10.1007/s12013-011-9276-3
  34. Weaver, C. T. and R. D. Hatton. 2009. Interplay between the TH17 and TReg cell lineages: a (co-) evolutionary perspective. Nat. Rev. Immunol. 9: 883-889. https://doi.org/10.1038/nri2660
  35. Khatami, M. 2009. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem. Biophys. 55: 55-79. https://doi.org/10.1007/s12013-009-9059-2
  36. Erdman, S. E. and T. Poutahidis. 2010. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol. 38: 76-87. https://doi.org/10.1177/0192623309354110
  37. Connolly, E. C., J. Freimuth, and R. J. Akhurst. 2012. Complexities of TGF-beta Targeted Cancer Therapy. Int. J. Biol. Sci. 8: 964-978. https://doi.org/10.7150/ijbs.4564

Cited by

  1. Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice vol.2015, pp.None, 2014, https://doi.org/10.1155/2015/630760
  2. Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy vol.30, pp.4, 2014, https://doi.org/10.1007/s40259-016-0176-3
  3. Immune analysis of expression of IL-17 relative ligands and their receptors in bladder cancer: comparison with polyp and cystitis vol.17, pp.None, 2014, https://doi.org/10.1186/s12865-016-0174-8
  4. Survival Rate of Patients with Bladder Cancer in Yazd, Central Province of Iran vol.11, pp.5, 2014, https://doi.org/10.5812/ijcm.61436
  5. TGF-β and microRNA Interplay in Genitourinary Cancers vol.8, pp.12, 2014, https://doi.org/10.3390/cells8121619
  6. The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development vol.22, pp.9, 2021, https://doi.org/10.3390/ijms22094483
  7. The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer vol.8, pp.6, 2014, https://doi.org/10.1016/j.gendis.2020.10.002
  8. Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA vol.19, pp.1, 2014, https://doi.org/10.1186/s12957-021-02231-4